Sarcopenia Treatment Market Report 2026

The sarcopenia treatment market size has grown strongly in recent years. It will grow from $3.72 billion in 2025 to $3.94 billion in 2026 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to growing elderly population base, increasing awareness of age-related muscle loss, reliance on physical therapy and nutritional support, limited availability of approved drug therapies, rising incidence of mobility-related disorders.

The sarcopenia treatment market size is expected to see strong growth in the next few years. It will grow to $4.97 billion in 2030 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to development of novel pharmacological treatments, increasing focus on early diagnosis and intervention, growing healthcare spending on geriatric care, rising prevalence of chronic diseases affecting muscle health, expanding clinical trials targeting muscle regeneration. Major trends in the forecast period include increasing use of combined pharmacological and exercise-based interventions, growing adoption of nutritional supplementation in sarcopenia management, rising clinical research on myostatin inhibitors and anabolic agents, increased diagnosis of sarcopenia in elderly populations, expanding integration of physical therapy in treatment pathways.

The increasing prevalence of malnutrition is expected to drive the growth of the sarcopenia treatment market in the coming years. Malnutrition refers to deficiencies, excesses, or imbalances in a person’s intake of energy and nutrients, encompassing both undernutrition and diet-related conditions such as overweight, obesity, and noncommunicable diseases. Treatments for sarcopenia help manage the coexisting effects of malnutrition and muscle loss in older adults through interventions like nutritional therapy and exercise, aiming to improve muscle mass, strength, and overall nutritional status. For example, in January 2025, a report published by the United States Department of Agriculture, a US-based government agency, indicated that household food insecurity affected 17.9% of families with children in 2023, impacting roughly 6.5 million households. Therefore, the rise in malnutrition is supporting growth in the sarcopenia treatment market.

Key companies in the sarcopenia treatment market are increasingly focusing on advanced clinical studies to develop better treatment options. Clinical studies are systematic investigations conducted on human subjects to evaluate the safety, efficacy, and outcomes of medical interventions. For instance, in September 2023, Biophytis, a France-based biotechnology company, announced FDA authorization to initiate the SARA-31 Phase 3 study in sarcopenia. The study aims to assess the efficacy and safety of Sarconeos (BIO101) in treating sarcopenic patients at risk of motor disability. This represents a significant advancement in pharmaceutical and technological approaches to sarcopenia, offering potential benefits for patients with severe disease. It is the first Phase 3 study in sarcopenia approved by the FDA and will enroll approximately 900 patients over 65 years old with sarcopenia, low walking speed, and reduced hand grip strength. Primary endpoints include assessing the risk of major mobility disability (MMD), walking speed, hand grip strength, and patient-reported quality of life.

In August 2023, Eli Lilly and Company, a US-based pharmaceutical company, acquired Versanis Bio for $1.925 billion. Through this acquisition, Lilly expanded its portfolio to include Versanis’ leading asset, bimagrumab, which is currently being evaluated in a Phase 2b study both as a standalone treatment and in combination with semaglutide for adults with overweight or obesity. Versanis Bio, based in the US, specializes in developing treatments for sarcopenia.

Major companies operating in the sarcopenia treatment market are Pfizer Inc, F Hoffmann La Roche, Merck Sharp And Dohme Corp, AbbVie Inc, Bayer AG, Novartis AG, Sanofi SA, Abbott Laboratories Inc, GlaxoSmithKline plc, Eli Lilly And Company, BASF SE, Nestle Health Science, Haleon Group Of Companies, DSM, Amway Corporation, Perrigo Company PLC, Intas Pharmaceuticals Ltd, Zydus Lifesciences, Fermenta Biotech Limited, Metagenics LLC, Makers Nutrition LLC, NutraScience Labs, AstaReal AB, NutraPak USA, BioThrive Sciences, Wellona Pharma, Healing Pharma India Pvt Ltd, Nutrafill.

North America was the largest region in the sarcopenia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sarcopenia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sarcopenia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately affected the sarcopenia treatment market by increasing costs of imported pharmaceuticals, nutritional supplements, biologics, and rehabilitation equipment used in treatment and management. These impacts are most visible in hospital and specialty clinic settings across north america and europe, where advanced therapies are widely adopted. Tariffs are also driving localization of drug manufacturing, regional sourcing of supplements, and domestic production of rehabilitation devices, which may support long-term market resilience and affordability.

The sarcopenia treatment market research report is one of a series of new reports that provides sarcopenia treatment market statistics, including sarcopenia treatment industry global market size, regional shares, competitors with a sarcopenia treatment market share, detailed sarcopenia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the sarcopenia treatment industry. This sarcopenia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Sarcopenia treatment refers to medical and lifestyle interventions aimed at counteracting age-related muscle loss and maintaining or improving skeletal muscle mass and function. The goal is to reduce muscle loss, enhance muscle strength, and improve overall physical function and mobility.

The main types of sarcopenia treatments include protein supplements, vitamin B12 supplements, vitamin D and calcium supplements, and others. Protein supplements are dietary or bodybuilding products available as protein bars, powders, or shakes, derived from whey, plant, or meat sources. These treatments address both primary and secondary sarcopenia and can be administered via oral, parenteral, or enteral routes. They are distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others.

The sarcopenia treatment market consists of revenues earned by entities by providing nutritional therapy, combination therapy, and muscle strength. The market value includes the value of related goods sold by the service provider or included within the service offering. The sarcopenia market also includes sales of muscle stimulators, orthopedic braces and supports, joint replacement implants, anabolic agents, and more. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.